For
immediate release
|
17 October
2024
|
ANGLE plc ("the
Company")
PUBLICATION DEMONSTRATES
POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE
CANCER
Parsortix enriched CTCs
detected at high rates in localised disease
Multi-marker profiling of
CTCs could support development of targeted therapies and help
stratify patients in clinical trials
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, is pleased to announce the publication of research investigating a panel of known
prostate cancer gene transcripts in CTCs, undertaken by the
Comprehensive Cancer Center at the Medical University of
Vienna.
Researchers used the
Parsortix® system to isolate and harvest CTCs from 38
localised and metastatic prostate cancer patients. CTCs were then
analysed using a range of molecular techniques which enabled
multiple biomarkers to be simultaneously analysed.
The study demonstrated the highly
effective capture of CTCs using the Parsortix system, with 67% of
localised prostate cancer patients positive for CTC biomarker(s) at
baseline and 77% positive for CTC biomarker(s) after
treatment.
The findings indicated a strong
correlation between specific CTC biomarkers and clinical
parameters, such as tumour grade and stage, suggesting that
multi-marker CTC analysis could aid in risk stratification for
patients. This adds to the body of evidence supporting ANGLE's
large pharma strategy, highlighting the potential to inform patient
selection for clinical trials in the development of targeted
therapies.
Chief Scientific Officer, Karen Miller,
commented:
"This study supports our pharma
services business by demonstrating how a Parsortix-enriched,
CTC-based multi-marker approach can enhance the development of
targeted therapies and improve patient stratification in clinical
trials. This approach could ultimately lead to the development of
new classes of drugs which are more targeted and provide better
outcomes for patients, all of which may require a Parsortix-based
companion diagnostic to support regulatory clearance."
The research, published as a
peer-reviewed publication in the journal Clinical and Experimental
Metastasis, is available online at
https://angleplc.com/resources/publications/.
For
further information:
ANGLE plc
|
+44
(0) 1483 343434
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected CTC harvesting technology known as the
Parsortix® PC1 System enables complete downstream
analysis of the sample including whole cell imaging and proteomic
analysis and full genomic and transcriptomic molecular
analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Products
include the Parsortix system, associated consumables and assays.
The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made
assay development and clinical trial testing for pharma.
Over 100 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com
Any reference to regulatory
authorisations such as FDA clearance, CE marking or UK MHRA
registration shall be read in conjunction with the full intended
use of the product:
The Parsortix® PC1 system is an in vitro diagnostic
device intended to enrich circulating tumor cells (CTCs) from
peripheral blood collected in K2EDTA tubes from patients
diagnosed with metastatic breast cancer. The system employs a
microfluidic chamber (a Parsortix cell separation cassette) to
capture cells of a certain size and deformability from the
population of cells present in blood. The cells retained in the
cassette are harvested by the Parsortix PC1 system for use in
subsequent downstream assays. The end user is responsible for the
validation of any downstream assay. The standalone device, as
indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease
management and/or treatment decisions.
All results reported in this
announcement and any other products and services are for research
use only and not for use in diagnostic procedures.